论文部分内容阅读
目的与方法:用分子生物学工程方法,表达和纯化kinectin蛋白作为抗原,用ELISA检测神经系统肿瘤、正常人和肝癌病人血清中kinectin抗体的阳性率。结果:正常人血清中kinectin检出率为5%,胶质瘤、脑膜瘤及垂体瘤患者血清中抗体检出率分别是43%、5%、3%,较肝癌病人血清中kinectin抗体检出率低(48%)。且检出率与患者性别、年龄、肿瘤大小、肿瘤分类和肿瘤分级无关。结论:kinectin与神经系统肿瘤有很强的相关性,可作为判定神经系统肿瘤的标志之一。
Objective and Methods: Using molecular biology engineering method, kinectin protein was expressed and purified as antigen, and the positive rate of kinectin antibody in the serum of nervous system tumor, normal human and liver cancer patient was detected by ELISA. Results: The detection rate of kinectin in normal human serum was 5%. The detection rates of serum antibodies in glioma, meningiomas and pituitary adenomas were 43%, 5% and 3%, respectively, which were higher than those in patients with hepatocellular carcinoma Low rate (48%). And the detection rate and the patient’s gender, age, tumor size, tumor classification and tumor grade has nothing to do. Conclusion: There is a strong correlation between kinectin and nervous system tumors, which can be used as one of the markers to judge the nervous system tumors.